Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcus Biosciences (RCUS) EPS (Basic) (2017 - 2025)

Arcus Biosciences has reported EPS (Basic) over the past 9 years, most recently at -$0.9 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 12.62% year-over-year to -$0.9; the TTM value through Dec 2025 reached -$3.31, down 6.77%, while the annual FY2025 figure was -$3.29, 4.78% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.9 at Arcus Biosciences, up from -$1.27 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $4.04 in Q4 2021 and troughed at -$1.27 in Q3 2025.
  • A 5-year average of -$0.71 and a median of -$1.02 in 2024 define the central range for EPS (Basic).
  • On a YoY basis, EPS (Basic) climbed as much as 564.37% in 2021 and fell as far as 3800.0% in 2021.
  • Year by year, EPS (Basic) stood at $4.04 in 2021, then crashed by 123.02% to -$0.93 in 2022, then decreased by 16.13% to -$1.08 in 2023, then rose by 4.63% to -$1.03 in 2024, then grew by 12.62% to -$0.9 in 2025.
  • Business Quant data shows EPS (Basic) for RCUS at -$0.9 in Q4 2025, -$1.27 in Q3 2025, and -$1.14 in Q1 2025.